Low-Dose Intravenous Ketamine Bolus versus Conventional Technique for Reduction of Upper and Lower Extremity Fractures in Children: A Randomized Controlled Clinical TrialMehdi Nasr Isfahani, Narges Shahverdi, Keihan GolshaniDepartment of Emergency Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Background: Ketamine administration in higher dosage causes some adverse reactions. This study was aimed to evaluate the effect of low-dose intravenous ketamine bolus versus conventional injection for reduction of upper and lower extremity fractures in children. Materials and Methods: In this study 198 patients with extremity fractures were enrolled. The patients were randomly assigned to two groups. In the intervention group, ketamine 1% was administered at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was injected for 30 to 60 seconds. Then outcomes were measured and satisfaction of patients and physicians were recorded. Results: Results showed that the successful sedation rate in the low dose ketamine group was significantly lower, as compared to the control group (7% vs 100%) (p<0.001). Moreover, In terms of duration of drug effect and of recovery, the low dose ketamine group were significantly lower compared with the group receiving higher dosage of ketamine (p<0.05). We also found that the rate of neurological (20.4 % vs 5%) and physiological (10.2% vs. 2%) side effects in the control group was significantly higher. (p<0.05). Conclusion: The findings of this study did not show any beneficial effects of low-dose intravenous ketamine bolus, in sedating pediatric patients, suggesting that it should not be considered as a treatment in accompany with standard therapy for control of pain in a short period of time. Keywords: low-dose intravenous ketamine bolus, fracture, children
Mehdi Nasr Isfahani, Narges Shahverdi, Keihan Golshani. Low-Dose Intravenous Ketamine Bolus versus Conventional Technique for Reduction of Upper and Lower Extremity Fractures in Children: A Randomized Controlled Clinical Trial. . 9999; 0: 0-0
Corresponding Author: Narges Shahverdi, Iran |
|